Amelie Simonnet

Motac provides highly-specialised preclinical research services for the pharmaceutical and biotechnology industries, to support the discovery and development of novel therapies for neurological and psychiatric disorders. This is enabled through our extensive expertise and world-class research capabilities in neurodegenerative conditions, particularly Parkinson’s disease, other movement disorders and cognitive disorders. We specialize in preclinical proof-of-concept and efficacy studies. Motac has unparalleled ability to offer access to the best available models of these conditions, underpinned by first-class scientific understanding, in a commercial environment, with a strong emphasis on quality and timeliness. Motac personnel have published widely in the highest-quality, peer-reviewed, scientific journals for several decades. They have been instrumental in elucidation of the brain mechanisms that mediate disorders of movement leading directly to the introduction of new treatments. Motac also has an intellectual property portfolio including new chemical entities and novel therapeutic targets for the treatment of movement disorders, which we are developing through strategic alliances and partnerships.